Find Clinical Trials | Cedars-Sinai

159 results found

Anus, Bones and Joints, Brain and Nervous System, Breast, Cervix ...

Allogenic Blood-Derived Natural Killer Cells in Cancer Refractory to Conventional Therapy

The purpose of this study is to evaluate a blood-derived experimental therapy in patients who have refractory cancer that has failed conventional, standard-of-care therapy. Researchers will use natural killer (NK) cells to create the study ...

Breast

Shorter Anthracycline-Free Chemo Immunotherapy in Early Triple-Negative Breast Cancer

The purpose of this study is to compare the standard-of-care chemo-immunotherapy (carboplatin/paclitaxel followed by adriamycin/cyclophosphamide plus pembrolizumab, given in 6 months) treatment for early-stage, triple-negative breast cancer to a shorter non-anthracycline chemo-immunotherapy treatment (carboplatin docetaxel ...

Pancreas

Metastatic Pancreatic Cancer: ABTL0812 in Combination With FOLFIRINOX

The purpose of this study is to evaluate the benefits and risks of adding an investigational drug called ABTL0812 to chemotherapy in adults who have been diagnosed with pancreatic cancer. The study aims to determine ...

Breast, Cervix, Esophagus, Kidney, Larynx, Liver, Lung, Other Digestive Organ ...

Bristol Myers Squibb, CA1201001,1/2, Open-Label, Solid Tumors, BMS-986449, +/- Chemo or Nivolumab

Primary Objective: To characterize the safety and tolerability, and to establish the MTD, MAD, and/or RP2D(s) of oral BMS-986449, administered as monotherapy and in combination with nivolumab, to participants with advanced cancer Secondary Objectives: To characterize ...

Breast, Cervix, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, Other Female ...

Georgiamune, GIM122-CT01, Ph 1/2, Open, Advanced Solid Malignancies, Single Agent GIM-122

Objectives: Primary Objective Dose Escalation and Enrichment (Part A) To characterize the safety and tolerability of GIM-122 as a single agent in subjects with programmed cell death protein-1 (PD-1)/programmed cell death ligand-1(PD-L1) refractory/resistant advanced solid ...